ClinicalTrials.gg
RecruitingNCT06781762STRIVE (Acute)Updated Oct 1, 2025

Short-term Impacts of Endocrine Therapy on Cardiovascular and Brain Health Outcomes in Breast Cancer

An observational study in Breast Cancer Females, sponsored by University of Toronto. Recruiting at 1 site in Canada. Open to female participants, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-10-01.

Sponsored by University of Toronto · Observational

How we know

From the registry’s dates

  • Started Jun 2025; still recruiting 1 year 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
40
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 53 studies in Obesity by University of Toronto — 4 open to participants now, 7 under way, none of them phase 3. Obesity · University of Toronto.

Planned enrollment
Largest of 12
40 · median 1
Started
2025
with 1 other
Observational
12 of 53
1 open now
Registered
52nd of 53
by date

Among the 53 studies in Obesity by University of Toronto, this one has the largest planned enrollment of the 12 observational ones that give a count, is one of 2 that started in 2025, is one of 12 observational ones, and was the 52nd registered.

Obesity

11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.

Browse Obesity studies →

Open to participants now

4 of the 53 studies in Obesity by University of Toronto are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 1,352 Obesity studies recruiting now, 382 (28%) set no upper age limit and 867 (64%) stop at 75 or younger; 169 take children under 18; 491 take healthy volunteers.

This study: female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 53 studies in Obesity by University of Toronto, or all of them as a file.
02

Study summary

Aromatase inhibitors are the most used endocrine therapy for hormone-positive breast cancer. While there is a clear linear relationship between the duration of aromatase inhibitor use and the cumulative incidence of cardiovascular events and mortality, the underlying mechanisms contributing to this risk remain unknown. This study will characterize the short-term effects of aromatase inhibitor therapy on established and novel health indices for cardiovascular diseases in breast cancer patients.

Using a longitudinal case-control design this study will assess the effects of short-term (first 6 months) aromatase inhibitor use in breast cancer patients compared to age- and BMI-matched controls, aiming to determine the cardiovascular, metabolic, and behavioural health impacts of endocrine treatment during this early period. Specifically, our objectives are as follows:

  1. To examine the effects of aromatase inhibitor therapy on early risk indicators for cardiovascular disease in the peripheral vasculature and heart, including blood biomarkers (lipids), blood pressure, aortic and peripheral stiffness, carotid artery stiffness and intima media thickness, endothelial function, and left ventricular ejection fraction, longitudinal strain, volumes, and mass, including the responsiveness of the cardiovascular system to an oral glucose tolerance test, in breast cancer survivors compared to controls.
  2. To examine the effects of aromatase inhibitor therapy on factors related to cerebrovascular health, autonomic regulation, and cognitive function, including BDNF, heart rate variability, cerebrovascular function in response to a supine-sit-stand maneuver and squatting challenge, and a core battery of cognitive function tests, in breast cancer survivors compared to controls.
  3. To examine the effects of aromatase inhibitor therapy on body composition and bone mineral density, along with assessments of glycemic regulation in response to an oral glucose tolerance test and in 24h periods of free-living (continuous glucose monitoring), in breast cancer survivors compared to controls.
  4. To examine the effects of aromatase inhibitor therapy on lifestyle factors (behavioural), including diet, physical activity (including cardiorespiratory fitness), sleep, stress, and quality of life, in breast cancer survivors compared to controls.

The investigators hypothesize that cardiovascular and metabolic health outcomes will be similar between breast cancer survivors and controls at baseline but will deteriorate relative to controls within the first 6 months of aromatase inhibitor therapy.

03

Conditions studied

  • Breast Cancer Females

Browse trials for

Keywords

  • Aromatase Inhibitors
  • Breast Cancer Females
  • Heart Disease Risk Factors
  • Obesity
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
Female
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Case participants will be recruited from Princess Margaret Cancer Centre in Toronto. Control participants will be local participants in the greater Toronto area, recruited through posters, newsletters, social media advertisements, and word of mouth.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Case group:

  • Biologically female
  • with natural (no bilateral oophorectomy) amenorrhea for at least 1 year
  • If using hormone replacement therapy, limit of a maximum of 3 years of treatment but not within the last 6 months.
  • Diagnosis of stage I, II, or III breast cancer
  • Hormone receptor positive breast cancer
  • HER negative (ER+/PR+/HER-) breast cancer
  • Confirmed to start aromatase inhibitor therapy for the first time in next 2-3 months
  • Received surgery/radiation therapies

Control group:

  • Biologically female
  • Post-menopausal with natural (no bilateral oophorectomy) amenorrhea for at least 1 year
  • If using hormone replacement therapy, limit of a maximum of 3 years of treatment but not within the last 6 months.

Exclusion criteria

Exclusion Criteria:

  • Previous treatment using tamoxifen endocrine therapy in a pre-or peri-menopausal setting
  • Major signs or symptoms of cardiovascular diseases, diabetes, or renal disease (taken from the American College of Sports Medicine's Guidelines for Exercise Testing and Prescription 11th edition Table 2.1: pain or discomfort in the chest, neck, jaw, arms with rest or exercise, shortness of breath at rest or with mild exertion, dizziness or syncope, loss of balance or passing out, ankle edema, palpitations or tachycardia, intermittent claudication, known heart murmur, unusual fatigue with usual activities.)
  • American Heart Association's absolute or relative for symptom-limited maximal exercise testing (myocardial infarction, aortic or coronary artery stenosis, heart failure, pulmonary embolism or deep vein thrombosis, inflammation of the heart (myocarditis, pericarditis, and/or endocarditis), uncontrolled cardiac arrythmia, advanced or complete electrical heart block, stroke or transient ischemia attack, blood pressure >200mmHg/100mmHg, a cancer diagnosis other than skin cancer)
  • Unable to provide or communicate in English
  • Mobility limitations to exercise testing (i.e., wheelchair, walker use, limp impeding walking)
  • Extreme claustrophobia
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
40 participants (estimated)
Patient registry
No
Biospecimen retention
Samples without dna

Groups and cohorts

  • Breast Cancer Patients Receiving Aromatase Inhibitor

    Breast Cancer patients using aromatase inhibitors for 6 months

    Other: N/A (Usual Care)

  • Matched Non-Cancer Controls

    Arm Description: A woman without a history of cancer will be recruited to match each patient with breast cancer on age and BMI (within 3 years and 3 kg/m2, whenever possible)

Interventions

  • OtherN/A (Usual Care)

    BC survivors will be using aromatase inhibitors as prescribed in their usual care treatment.

06

What researchers measure

Primary outcomes

  1. Aortic Stiffness

    Aortic stiffness, measured non-invasively by pulse wave velocity, will be assessed using applanation tonometry. Measurements will be taken at rest and every 30min during a 2h oral glucose tolerance test.

    Time frame: Baseline, 6 months

Secondary outcomes

  1. Brachial Artery Endothelial Function

    Endothelial function will be assessed using the gold standard method of flow mediated dilation (FMD) using non-invasive duplex ultrasound (GE Vivid IQ) and edge-tracking software. Measurements will be taken at rest and every 30min during a 2h oral glucose tolerance test.

    Time frame: Baseline, 6 months

  2. Carotid Artery Stiffness

    Functional assessment of the carotid artery stiffness will be assessed using B-mode ultrasound and artery edge-tracking software

    Time frame: Baseline, 6 months

  3. Carotid Intima Media Thickness

    Structural assessment of the carotid artery thickness will be assessed using B-mode ultrasound and artery edge-tracking software

    Time frame: Baseline, 6 months

  4. Left Ventricular Ejection Fraction (LVEF)

    Cardiac outcomes will be assessed via echocardiography (GE Vivid IQ) and analyzed using Echopac software, represented as a % using the following formula: stroke volume/end diastolic volume x 100%.

    Time frame: Baseline, 6 months

  5. Global Longitudinal Strain

    Cardiac outcomes will be assessed via echocardiography (GE Vivid IQ) and analyzed using Echopac software, expressed as a percentage of the relative change in length of the left ventricle through a cardiac cycle.

    Time frame: Baseline, 6 months

  6. Left Ventricular Diastolic Function

    Cardiac outcomes will be assessed via echocardiography (GE Vivid IQ) and analyzed using Echopac software, assessed by the ratio of peak early diastolic velocity to peak mitral valve velocity (E/A ratio).

    Time frame: Baseline, 6 months

  7. Arterial Stiffness

    Measured by Pulse Wave Velocity (PWV) of the arm and leg

    Time frame: Baseline, 6 months

  8. Cerebrovascular Response

    Cerebral blood flow velocity response (delta change compared to rest) of the middle cerebral artery will be assessed using transcranial Doppler ultrasound (Neurovision Transcranial Doppler System Model 500M) in accordance with recent guidelines, in response to postural changes (sit-to-stand) and exercise (squatting).

    Time frame: Baseline, 6 months

  9. Brain Derived Neurotrophic Factor

    Brain derived neurotrophic factor will be assessed via fasted venipuncture using in-house assays.

    Time frame: Baseline, 6 months

  10. Lipid profile

    HDL, LDL, total Cholesterol, Triglycerides analyzed from blood serum using a clinical assay at a core lab.

    Time frame: Baseline, 6 months

  11. Hemoglobin A1c

    Analyzed from blood plasma using a clinical assay at a core lab.

    Time frame: Baseline, 6 months

  12. Insulin resistance

    Calculated as Homeostatic Model Assessment for Insulin Resistance (HOMA-IR) from fasting blood measures of glucose and insulin, analyzed using a clinical assay at a core lab. Matsuda Index will also be calculated using a standard equation requiring fasting insulin and glucose and area under the curve of the post-ingestion of 75g of glucose insulin and glucose concentrations measured at 30, 60, 90 and 120 minutes.

    Time frame: Baseline, 6 months

Other outcomes

  1. Cardiorespiratory fitness

    Measured as peak volume of oxygen consumption via indirect calorimetry during a cardiopulmonary exercise test on a cycle ergometer.

    Time frame: Baseline, 6 months

  2. Framingham 10-year cardiovascular risk (%)

    Calculated using the standardized scoring system where sex-specific points are assigned to age, systolic blood pressure (dependent on treatment status), HDL, total cholesterol, smoking and diabetes status. The range for females is 0-30% where a higher score indicates a greater risk of cardiovascular disease in the next 10 years.

    Time frame: Baseline, 6 months

  3. Heart Rate Recovery

    Measured as the difference between peak heart rate during the cardiorespiratory fitness test and heart rate 2-minutes into active recovery after stopping the exercise test.

    Time frame: Baseline, 6 months

  4. Heart Rate Variability

    Measured as the variability in beat-to-beat heart rate during supine rest.

    Time frame: Baseline, 6 months

  5. avO2 difference

    Measured by a non-invasive optical technique used to assess tissue oxygenation and hemodynamics (Near-Infrared Spectroscopy - NIRS) at rest, and during cycling exercise at ventilatory threshold, respiratory compensation point, and peak oxygen uptake.

    Time frame: Baseline, 6 months

  6. Cardiac Output

    Measured continuously by a finger cuff (Finger Arterial Pressure - Finapres) at rest, and during cycling exercise at ventilatory threshold, respiratory compensation point, and peak oxygen uptake.

    Time frame: Baseline, 6 months

  7. Stroke Volume

    Measured continuously by a finger cuff (Finger Arterial Pressure - Finapres) at rest, and during cycling exercise at ventilatory threshold, respiratory compensation point, and peak oxygen uptake.

    Time frame: Baseline, 6 months

  8. Resting Blood Pressure

    Measured as the average of the last 5 of 6 blood pressure measurements taken 60 seconds apart using an automatic blood pressure device.

    Time frame: Baseline, 6 months

  9. Beat-by-beat Blood Pressure

    Measured continuously by a finger cuff (Finger Arterial Pressure - Finapres) at rest, and during cycling exercise at ventilatory threshold, respiratory compensation point, and peak oxygen uptake.

    Time frame: Baseline, 6 months

  10. Glucose Levels

    Measured during a 10-day period by a Dexcom G7 Continuous Glucose Monitor (CGM)

    Time frame: Baseline, 6 months

  11. Hemoglobin

    Analyzed from blood plasma using a clinical assay at a core lab.

    Time frame: 6 months

  12. Whole-body fat mass

    Measured using a body composition device (BodPod) to estimate whole body fat (in kg and %).

    Time frame: Baseline, 6 months

  13. Whole-body fat-free mass

    Measured using a body composition device (BodPod) to estimate whole body fat free mass (in kg and %).

    Time frame: Baseline, 6 months

  14. Waist Circumference

    Circumference of the waist measured using an inelastic tape

    Time frame: Baseline, 6 months

  15. Hip Circumference

    Circumference of the hip measured using an inelastic tape

    Time frame: Baseline, 6 months

  16. Neck Circumference

    Circumference of the neck measured using an inelastic tape

    Time frame: Baseline, 6 months

  17. Body weight

    Assessed fasted in lab using a calibrated scale

    Time frame: Baseline, 6 months

  18. Body mass index (BMI)

    Calculated from a measurement of height using a stadiometer and body weight (detailed above).

    Time frame: Baseline, 6 months

  19. Dietary intake

    Various components of dietary intake including macronutrients and micronutrients will be assessed through 3-day food records over 2 weekdays and 1 weekend collected using ASA-24 online system.

    Time frame: Baseline, 6 months

  20. Diet quality

    An overall measure of alignment with Canada's dietary guidelines measured via the Healthy Eating Food Index-2019 calculated from 3-day diet records

    Time frame: Baseline, 6 months

  21. Depression & Anxiety

    Measured by the Hospital Anxiety and Depression Scale (HADS); score ranges from 0-21 for each of depression and anxiety with a higher score indicating more severe depression or anxiety

    Time frame: Baseline, 6 months

  22. Autonomic symptoms

    Assessed by the COMPASS 31 (Composite Autonomic Symptom Score) questionnaire. This questionnaire provides clinically relevant scores of autonomic symptom severity. Scores range from 0 to 31 with questions in six domains: orthostatic intolerance, vasomotor, secretomotor, gastrointestinal, bladder, and pupillomotor, with a higher scoring indicating worse autonomic dysfunction.

    Time frame: Baseline, 6 months

  23. Cognitive Function: Verbal Fluency

    Assessed using the Controlled Oral Word Association of the Multilingual Aphasia Exam (verbal fluency), with higher number of words produced indicative of better cognitive health.

    Time frame: Baseline, 6 months

  24. Cognitive Function: Verbal Learning & Memory

    Assessed the Hopkins Verbal Learning Test (learning, memory) with an immediate recall, delayed recall, and recognition accuracy from a list of 12 words. Higher number of words are indicative of better cognitive health.

    Time frame: Baseline, 6 months

  25. Cognitive Function: Processing Speed

    Assessed by the Trail Making Test (attention, speed, executive function). Shorter test time on 2 forms of the test is indicative of better cognitive health.

    Time frame: Baseline, 6 months

  26. Cognitive Impairment (Composite Measure)

    Assessed by Global Deficit Score (GDS). GDS is calculated as an average score from 3 tests previously described in outcomes 36, 37, and 38: 1) Hopkins Verbal Learning Test (learning, memory), 2) Trail Making Test (attention, speed, executive function), 3) Controlled Oral Word Association of the Multilingual Aphasia Exam (verbal fluency). Each subtest of the GDS has a complex scoring system, detailed above, with higher values indicating greater cognitive deficits.

    Time frame: Baseline, 6 months

  27. Cancer-specific Quality of life (only assessed in cancer group): General

    Assessed using the Functional Assessment of Cancer Therapy - General (FACT-G). This is a patient-reported outcome measurement used to assess health-related quality of life in patients with a history of cancer. The FACT-G is calculated from the sum of four subscales on general health related quality of life with a range of 0-108 points. Higher scores on each scale is indicative of better quality of life.

    Time frame: Baseline, 6 months

  28. Cancer-specific Quality of life (only assessed in cancer group): Endocrine

    Assessed using the Functional Assessment of Cancer Therapy - Endocrine (FACT-ES). This is a patient-reported outcome measurement used to assess health-related quality of life in patients with a history of cancer. The FACT-ES is a score of 19 questions with scores ranging from 0-76. Higher scores on each scale is indicative of better quality of life.

    Time frame: Baseline, 6 months

  29. Cancer-specific Quality of life (only assessed in cancer group): Cognitive

    Assessed using the Functional Assessment of Cancer Therapy - Cognitive (FACT-Cog). This is a patient-reported outcome measurement used to assess health-related quality of life in patients with a history of cancer. The FACT-Cog contains 37 questions with a score of 0 to 132. Higher scores on each scale is indicative of better quality of life.

    Time frame: Baseline, 6 months

  30. Cancer-specific Quality of life (only assessed in cancer group): Fatigue

    Assessed using the Functional Assessment of Cancer Therapy - Fatigue (FACT-F). This is a patient-reported outcome measurement used to assess health-related quality of life in patients with a history of cancer. FACT-F is calculated from the sum of 13 questions. Higher scores on each scale is indicative of better quality of life.

    Time frame: Baseline, 6 months

  31. Musculoskeletal health

    Assessed using the Musculoskeletal Health Questionnaire (MSK-HQ). The MSK-HQ is a series of 15 questions with a range from 0-56 with higher scores being indicative of poorer MSK health.

    Time frame: Baseline, 6 months

  32. Musculoskeletal pain

    Assessed using the Brief Pain Inventory (BPI). The BPI is scored as the average of seven pain-related questions with a range of 0-10 with higher scores representing greater pain.

    Time frame: Baseline, 6 months

  33. Musculoskeletal osteoarthritis risk

    Assessed using the Western Ontario and McMaster Universities Osteoarthritis (WOMAC) Index. The WOMAC is a series of 17 questions resulting in a % (0-100) with higher scores indicative of greater osteoarthritis index.

    Time frame: Baseline, 6 months

  34. Musculoskeletal disability

    Assessed using the Disabilities of the Arm, Shoulder, and Hand (DASH) Questionnaire. The DASH contains 30 questions with scores of 0 to 100 with higher scores representing higher severity in disability.

    Time frame: Baseline, 6 months

  35. Cardiovascular risk

    Assessed using the INTERHEART Risk Score, a validated score for quantifying risk-factor burden without the use of laboratory testing (with higher scores indicating greater risk-factor burden).

    Time frame: Baseline, 6 months

  36. Gender-Related Factors

    Assessed by the Stanford Gender-related Variables for Health Research (GVHR) which includes questions related to seven gender-related variables: caregiver strain, work strain, independence, risk-taking, emotional intelligence, social support, and discrimination.

    Time frame: Baseline

  37. Health-related quality of life

    Assessed by RAND-36, where an independent score is provided for 8 scales ranging from 0 to 100 and 2 component summary scales ranging from 0-50 with a higher score indicating better quality of life.

    Time frame: Baseline, 6 months

  38. Psychosocial stress

    Assessed by the perceived stress scale (PSS-14) where individual scores can range from 0 to 56 with higher scores indicating higher perceived stress

    Time frame: Baseline, 6 months

  39. Sleep quality - subjective

    Subjectively assessed by the Pittsburgh Sleep Quality Index (PQSI), which measures components of sleep: sleep duration, disturbance, sleep latency, daytime dysfunction due to sleepiness, sleep efficiency, overall sleep quality, and sleep medication use, with higher scores reflecting poorer sleep quality. From these 7 questions, a global score of 0 to 21 is created with higher values indicative of poorer sleep quality.

    Time frame: Baseline, 6 months

  40. Sleep quantity - device measured

    Measured via Garmin smartwatch for the total sleep duration.

    Time frame: Baseline, 6 months

  41. Sleep quality - device measured

    Measured via Garmin smartwatch for the total sleep efficiency.

    Time frame: Baseline, 6 months

  42. Moderate-Vigorous Physical Activity

    Measured via Garmin smartwatch for time in moderate-vigorous physical activity in total minutes at this intensity.

    Time frame: Baseline, 6 months

  43. Physical activity: step counts

    Measured via Garmin smartwatch for daily step counts.

    Time frame: Baseline, 6 months

  44. Sedentary time

    Measured via Garmin smartwatch for time spent sitting.

    Time frame: Baseline, 6 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2025 (actual). Primary completion is estimated for Dec 2026, 18 months after the start.

Of 796 non-industry observational studies under Obesity, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 106. This study's planned 18 months is below that.

Counting every sponsor, half of 842 studies reached it within 39 months; a quarter within 17 and three quarters within 96.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 30, 2024
First posted
Jan 17, 2025
StartActual
Jun 6, 2025
Primary completionEst.
Dec 30, 2026
CompletionEst.
Dec 30, 2026
Last update
Oct 1, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 1, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06781762
Collaborators
Cancer Research Society, Canadian Institutes of Health Research (CIHR), Princess Margaret Hospital, Canada
Responsible party
Amy Kirkham (Assistant Professor, University of Toronto) — Principal investigator
First posted
Jan 17, 2025
Start date
Jun 6, 2025
Primary completion
Dec 30, 2026 (estimated)
Completion
Dec 30, 2026 (estimated)
Last update
Oct 1, 2025

Study contacts

Amy A. Kirkham, PhD
Contact
amy.kirkham@utoronto.ca
416-946-4069

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion